452 related articles for article (PubMed ID: 26378177)
1. Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.
Betancourt D; Ramos JC; Barber GN
J Virol; 2015 Dec; 89(23):11786-800. PubMed ID: 26378177
[TBL] [Abstract][Full Text] [Related]
2. Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.
Tezuka K; Okuma K; Kuramitsu M; Matsuoka S; Tanaka R; Tanaka Y; Hamaguchi I
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212930
[TBL] [Abstract][Full Text] [Related]
3. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
4. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
5. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
Wollmann G; Drokhlyansky E; Davis JN; Cepko C; van den Pol AN
J Virol; 2015 Jul; 89(13):6711-24. PubMed ID: 25878115
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic activity of vesicular stomatitis virus in primary adult T-cell leukemia.
Césaire R; Olière S; Sharif-Askari E; Loignon M; Lézin A; Olindo S; Panelatti G; Kazanji M; Aloyz R; Panasci L; Bell JC; Hiscott J
Oncogene; 2006 Jan; 25(3):349-58. PubMed ID: 16186807
[TBL] [Abstract][Full Text] [Related]
7. Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins.
Johnson JE; Schnell MJ; Buonocore L; Rose JK
J Virol; 1997 Jul; 71(7):5060-8. PubMed ID: 9188571
[TBL] [Abstract][Full Text] [Related]
8. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.
Heiber JF; Barber GN
J Virol; 2011 Oct; 85(20):10440-50. PubMed ID: 21813611
[TBL] [Abstract][Full Text] [Related]
9. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
Yu N; Puckett S; Antinozzi PA; Cramer SD; Lyles DS
J Virol; 2015 May; 89(10):5250-63. PubMed ID: 25741004
[TBL] [Abstract][Full Text] [Related]
10. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.
Ayala-Breton C; Barber GN; Russell SJ; Peng KW
Hum Gene Ther; 2012 May; 23(5):484-91. PubMed ID: 22171635
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic vesicular stomatitis virus administered by isolated limb perfusion suppresses osteosarcoma growth.
Kubo T; Shimose S; Matsuo T; Fujimori J; Sakaguchi T; Yamaki M; Shinozaki K; Woo SL; Ochi M
J Orthop Res; 2011 May; 29(5):795-800. PubMed ID: 21437961
[TBL] [Abstract][Full Text] [Related]
12. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
13. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
14. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
15. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
16. A recombinant vesicular stomatitis virus encoding CCR5-tropic HIV-1 receptors targets HIV-1-infected cells and controls HIV-1 infection.
Okuma K; Fukagawa K; Kohma T; Takahama Y; Hamaguchi Y; Ito M; Tanaka Y; Buonocore L; Rose JK; Hamaguchi I
Microbes Infect; 2017; 19(4-5):277-287. PubMed ID: 28025070
[TBL] [Abstract][Full Text] [Related]
17. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
18. Vesiculovirus neutralization by natural IgM and complement.
Tesfay MZ; Ammayappan A; Federspiel MJ; Barber GN; Stojdl D; Peng KW; Russell SJ
J Virol; 2014 Jun; 88(11):6148-57. PubMed ID: 24648451
[TBL] [Abstract][Full Text] [Related]
19. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
[TBL] [Abstract][Full Text] [Related]
20. [Vesicular stomatitis virus in the fight against cancer].
Janelle V; Poliquin L; Lamarre A
Med Sci (Paris); 2013 Feb; 29(2):175-82. PubMed ID: 23452604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
